These encouraging preclinical findings led to a Phase 1, double-blind, placebo-controlled clinical trial (NCT01041222) aimed at assessing the safety and tolerability of intrathecally administered ASO333611 in patients with SOD1 ALS [73]. Here, SOD1 is linked to amyotrophic lateral sclerosis.